ICER calls out Gilead, J&J, Novartis and more in latest report on 'unsupported' price increases

In the Institute for Clinical and Economic Review’s (ICER’s) annual price-hike report, the U.S. watchdog is taking several pharma majors to task over what it says are "unsupported" price increases.

Still, as is customary following the release of the cost increase data, many of the companies implicated in the review have been quick to hit back against the ICER’s findings.